Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Actinium Pharmaceuticals Inc (ATNM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Actinium Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.510 -0.550    -7.79%
15:21:21 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 268,248
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 6.470 - 6.970
Actinium Pharmaceuticals 6.510 -0.550 -7.79%

Actinium Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Actinium Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

49

Equity Type

ORD

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.

Contact Information

Address 100 Park Avenue 23rd Floor
New York, 10017
United States
Phone 646 677 3870
Fax -

Top Executives

Name Age Since Title
Elihu H. Estey - - Member of Clinical Advisory Board
Sandesh C. Seth 60 2012 Chairman & CEO
Sergio Giralt - 2014 Member of Scientific Advisory Board
David Colcher - 2018 Members of Nuclear Medicine Clinical Advisory Board
David A. Scheinberg 68 - Member of Clinical Advisory Board
Franklin Wong - 2018 Members of Nuclear Medicine Clinical Advisory Board
Hagop M. Kantarjian - - Member of Clinical Advisory Board
Jeffrey W. Chell 70 2018 Independent Director
Johannes Czernin - 2018 Members of Nuclear Medicine Clinical Advisory Board
Alexander Perl - - Member of Clinical Advisory Board
Hillard M. Lazarus - 2014 Member of Scientific Advisory Board
C. David Nicholson 69 2008 Lead Independent Director
Richard E. Champlin - 2014 Member of Scientific Advisory Board
Michael Yu - 2018 Members of Nuclear Medicine Clinical Advisory Board
Dan Pryma - 2018 Members of Nuclear Medicine Clinical Advisory Board
Ajit S. Shetty 77 2017 Independent Director
John M. Pagel - - Chairman of Scientific Advisory Board & Member of Clinical Advisory Board
Richard L. Wahl - - Member of Clinical Advisory Board
Joseph G. Jurcic - - Chairman of Clinical Advisory Board
Richard M. Stone - 2017 Member of Scientific Advisory Board
M. Yair Levy - 2014 Member of Scientific Advisory Board
Richard I. Steinhart 67 2013 Independent Director
Ghassan El-Haddad - 2018 Members of Nuclear Medicine Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ATNM Comments

Write your thoughts about Actinium Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
kurt vanmeerhaeghe
kurt vanmeerhaeghe Feb 18, 2023 8:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
get in before it's too late
kurt vanmeerhaeghe
kurt vanmeerhaeghe Nov 05, 2022 3:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
after the recent decline, time to buy more
Donna Saldi
Donna Saldi Apr 21, 2021 12:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy this investment today.....get in and hold!
Donna Saldi
Donna Saldi Mar 25, 2021 12:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy and holdA gem of a stock....gl........this is going to be a blockbuster....no joke
Donna Saldi
Donna Saldi Mar 01, 2021 7:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
100% engraftment,gals and guys!lovin this.....bullish!
Donna Saldi
Donna Saldi Feb 16, 2021 7:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy and hold.....no brainer!
Ehsan Haidari
Ehsan Haidari Jan 05, 2021 2:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is this a good or bad stock to buy?
Pete Pearson
Pyxis2025 Jan 05, 2021 2:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Long term good, short bad.
Duane Goodson
Duane Goodson Jan 04, 2021 11:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
Matthew Whittaker
Matthew Whittaker Dec 30, 2020 6:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pacific Edge (PEB) let's go! 🥳 🚀
Jorge Fabrizio
Jorge Fabrizio Oct 16, 2020 10:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
12.50!!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email